Scalable nanoprecipitation of niclosamide and in vivo demonstration of long-acting delivery after intramuscular injection
James J. Hobson, Alison C. Savage, Andrew B. Dwyer, Catherine Unsworth, Jonathan Massam, Usman Arshad, Henry Pertinez, Helen Box, Lee Tatham, Rajith K. R. Rajoli, Megan Neary, Joanne Sharp, Anthony Valentijn, Christopher David, Paul Curley, Neill J. Liptrott, Tom O. McDonald, Andrew Owen and Steve P. Rannard
The control of COVID-19 across the world requires the formation of a range of interventions including vaccines to elicit an immune response and immunomodulatory or antiviral therapeutics. Here, we demonstrate the nanoparticle formulation of a highly insoluble drug compound, niclosamide, with known anti SARS-CoV-2 activity as a cheap and scalable long-acting injectable antiviral candidate.
Link to article (if provided):
Published on 2021-03-10